Q-omics provides the consensus-scored UBE2L5 profile across patient tissues and cancer cell-line models. UBE2L5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, UBE2L5 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, UBE2L5 RNA expression shows 14,396 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where UBE2L5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2L5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2L5 survival associations across molecular data types. UBE2L5 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2L5 RNA expression–survival associations across cancer types. High UBE2L5 expression shows unfavorable associations in UVM, ACC, LGG and UCEC, but favorable associations in CESC and DLBC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for UBE2L5 RNA expression.
This table summarizes UBE2L5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for UBE2L5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2L5 shows lower tumor expression in COAD, BRCA and KICH and higher tumor expression in KIRC, HNSC and LIHC. The COAD box plot shows higher UBE2L5 RNA expression in normal versus tumor tissue (log2 FC = −0.537, t-test p < 0.001).
This table shows molecular features associated with UBE2L5 in patient tissues and cancer cell lines. In patient samples, UBE2L5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE2L5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma.
